Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies von Lemaire, M, D'Huyvetter, M, Lahoutte, T, Van Valckenborgh, E, Menu, E, De Bruyne, E, Kronenberger, P, Wernery, U, Muyldermans, S, Devoogdt, N, Vanderkerken, K

Volltext

Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow von Van Valckenborgh, E, Schouppe, E, Movahedi, K, De Bruyne, E, Menu, E, De Baetselier, P, Vanderkerken, K, Van Ginderachter, J A

Volltext

181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative von Aftimos, P.G., Punie, K., Decoster, L., Van Marcke de Lummen, C., Hebrant, A., Raicevic, G., Van Valckenborgh, E., Maes, B., Maetens, J., Collignon, J.J., van den Mooter, T.F.A., Fried-Vermeij, J., Demey, W., Tejpar, S., Peeters, M., Canon, J-L., Lybaert, W., Mebis, J., Rottey, S., De Grève, J.

Volltext

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation von Xu, D, Hu, J, Xu, S, De Bruyne, E, Menu, E, Van Camp, B, Vanderkerken, K, Van Valckenborgh, E

Volltext

Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells von Caers, J, Deleu, S, Belaid, Z, De Raeve, H, Van Valckenborgh, E, De Bruyne, E, DeFresne, M-P, Van Riet, I, Van Camp, B, Vanderkerken, K

Volltext

Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model von Van Valckenborgh, E, Matsui, W, Agarwal, P, Lub, S, Dehui, X, De Bruyne, E, Menu, E, Empsen, C, van Grunsven, L, Agarwal, J, Wang, Q, Jernberg-Wiklund, H, Vanderkerken, K

Volltext

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models von Deleu, S, Lemaire, M, Arts, J, Menu, E, Van Valckenborgh, E, King, P, Vande Broek, I, De Raeve, H, Van Camp, B, Croucher, P, Vanderkerken, K

Volltext

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model von Menu, E, Kooijman, R, Valckenborgh, E Van, Asosingh, K, Bakkus, M, Camp, B Van, Vanderkerken, K

Volltext

Implementation of precision medicine in (routine) cancer care in Belgium in a fair and equitable way von Schmitt, T, Delnord, M, Cauët, E, Van Valckenborgh, E, Van Den Bulcke, M

Volltext

Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma von Caers, J, Menu, E, De Raeve, H, Lepage, D, Van Valckenborgh, E, Van Camp, B, Alvarez, E, Vanderkerken, K

Volltext

Bone marrow endothelial cells as active players in the pathobiology of multiple myeloma von Vanderkerken, K, De Bruyne, E, Menu, E, Van Valckenborgh, E, Van Camp, B

Volltext

1725P Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations von McCrary, J.M., Van Valckenborgh, E., van Rooij, J., Van Steen, K., Vaht, M., Metspalu, A., Uitterlinden, A., Genuardi, M., Poirel, H.A., Bergmann, A.K.

Volltext

Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting von Vermaelen, K., Waeytens, A., Kholmanskikh, O., Van den Bulcke, M., Van Valckenborgh, E.

Volltext

Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model von VAN VALCKENBORGH, E, MINCHER, D, DI SALVO, A, VAN RIET, I, YOUNG, L, VAN CAMP, B, VANDERKERKEN, K

Volltext

Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients von DE BRUYNE, E, ANDERSEN, T. L, DE RAEVE, H, VAN VAICKENBORGH, E, CAERS, J, VAN CAMP, B, DELAISSE, J.-M, VAN RIET, I, VANDERKERKEN, K

Volltext

Specific roles for the P13K and the MEK-ERK pathway in IGF-I-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model von MENU, E, KOOIJMAN, R, VAN VALCKENBORGH, E, ASOSINGH, K, BAKKUS, M, VAN CAMP, B, VANDERKERKEN, K

Volltext

Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo von Van Valckenborgh, E, De Raeve, H, Devy, L, Blacher, S, Munaut, C, Noël, A, Van Marck, E, Van Riet, I, Van Camp, B, Vanderkerken, K

Volltext

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic von Bieghs, Liesbeth, Lub, Susanne, Fostier, Karel, Maes, Ken, Van Valckenborgh, Els, Menu, Eline, Johnsen, Hans E, Overgaard, Michael T, Larsson, Olle, Axelson, Magnus, Nyegaard, Mette, Schots, Rik, Jernberg-Wiklund, Helena, Vanderkerken, Karin, De Bruyne, Elke

Volltext

Targeting the IGF‐1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival... von Menu, Eline, Jernberg‐Wiklund, Helena, De Raeve, Hendrik, De Leenheer, Evy, Coulton, Les, Gallagher, Orla, Van Valckenborgh, Els, Larsson, Olle, Axelson, Magnus, Nilsson, Kenneth, Van Camp, Ben, Croucher, Peter, Vanderkerken, Karin

Volltext

Equity assessment in innovative cancer genomic interventions: the Can.Heal project von Molina-Barceló, A, Romeo-Cervera, P, Pinto-Carbó, M, Vanaclocha-Espí, M, de Pablo-Pardo, T, Alessandrello, R, Van Valckenborgh, E, van den Bulcke, M

Volltext